A Prospective, Randomized, Double-Blind Clinical Trial to Investigate the Efficacy of Autologous Bone Marrow Aspirate Concentrate During Arthroscopic Meniscectomy in Patients With Early Knee Osteoarthritis.

この研究はインパクトが大きい可能性があると判断されました。 OEのAIによるハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文の影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することができ、読者は将来の診療を形成する可能性が最も高い論文に焦点を当てることができます。

研究概要

Ninety-five patients with symptomatic meniscal tears and mild knee osteoarthritis were randomized to receive either an autologous bone marrow aspirate concentrate (BMAC) injection at the time of arthroscopic partial meniscectomy (APM) (n=44) or APM alone (n=39). The primary outcome of interest was the International Knee Documentation Committee (IKDC) score at one year postoperatively. Secondary outcomes included radiographic changes (Kellgren-Lawrence grade) at one year and various patient-reported outcome measures (PROMs), including the Knee injury and Osteoarthritis Outcome Score (KOOS), visual analog scale (VAS) for pain, and the Veterans RAND 12-Item Health Survey (VR-12), assessed at 3 months, 6 months, 1 year, and 2 years. Overall, the results revealed no significant differences in IKDC scores or radiographic outcomes between the BMAC and control groups at one year. However, a greater proportion of the BMAC group achieved the minimal clinically important difference (MCID) for KOOS Sport and KOOS Symptoms at one year. These findings suggest that while BMAC does not significantly improve primary outcomes compared to APM alone, it may enhance specific functional and symptomatic improvements.